By Stephen Nakrosis
Onconetix on Thursday said it named its interim Chief Financial Officer, Karina Fedasz, as interim Chief Executive Officer, effective immediately.
Also on Thursday, the biotechnology company said James Sapirstein resigned as executive chairman and as a member of the board.
Fedasz has helped companies raise capital, model and forecast business, manage cash flow and conduct mergers and acquisitions for more than two decades, Onconetix said. She has been interim CFO of Onconetix since June 2024. Before that, she worked with various clients, including a not-for-profit and an early-stage artificial intelligence and data-driven health and wellness tracker.
Prior to that, Fedasz was head of business development for Evofem Biosciences, and also served in various positions of increasing responsibility, including CFO, at IDW Media Holdings, Onconetix said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 03, 2025 18:34 ET (22:34 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.